Eyevensys Receives Investment From Boehringer Ingelheim

Eyevensys said it received an equity investment from the Boehringer Ingelheim Venture Fund. Further details were not available. The company raised about $2.1 million in its first round of funding in January 2012. It said early investors – Innobio, managed by CDC Entreprises; Inserm Transfert Initiative; and CapDecisif Management – plan to participate in the second round.

ArmaGen Technologies Raises $17m Series A

ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget